Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 20;16(1):578.
doi: 10.1007/s12672-025-01816-9.

Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions

Affiliations
Review

Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions

Nima Ghoreyshi et al. Discov Oncol. .

Abstract

Next-generation sequencing (NGS) has emerged as a pivotal technology in the field of oncology, transforming the approach to cancer diagnosis and treatment. This paper provides a comprehensive overview of the integration of NGS into clinical settings, emphasizing its significant contributions to precision medicine. NGS enables detailed genomic profiling of tumors, identifying genetic alterations that drive cancer progression and facilitating personalized treatment plans targeting specific mutations, thereby improving patient outcomes. This capability facilitates the development of personalized treatment plans targeting specific mutations, leading to improved patient outcomes and the potential for better prognosis. The application of NGS extends beyond identifying actionable mutations; it is instrumental in detecting hereditary cancer syndromes, thus aiding in early diagnosis and preventive strategies. Furthermore, NGS plays a crucial role in monitoring minimal residual disease, offering a sensitive method to detect cancer recurrence at an early stage. Its use in guiding immunotherapy by identifying biomarkers that predict response to treatment is also highlighted. Ethical issues related to genetic testing, such as concerns around patient consent and data privacy, are also important considerations that need to be addressed for the broader implementation of NGS. These include the complexities of data interpretation, the need for robust bioinformatics support, cost considerations, and ethical issues related to genetic testing. Addressing these challenges is essential for the widespread adoption of NGS. Looking forward, advancements such as single-cell sequencing and liquid biopsies promise to further enhance the precision of cancer diagnostics and treatment. This review emphasizes the transformative impact of NGS in oncology and advocates for its incorporation into routine clinical practice to promote molecularly driven cancer care.

Keywords: Biomarkers; Cancer diagnosis; Cancer treatment; Genomic profiling; Next-generation sequencing; Precision oncology.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Figure showing the key steps in NGS library construction, from DNA/RNA extraction to fragmentation, adapter ligation, amplification, and quality control, ensuring samples are ready for sequencing

Similar articles

Cited by

References

    1. Popova L, Carabetta VJ. The use of next-generation sequencing in personalized medicine. ArXiv; 2024. - PubMed
    1. Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. In: Seminars in thrombosis and hemostasis. Thieme Medical Publishers; 2024. - PubMed
    1. Kamps R, Brandão RD, van den Bosch BJ, Paulussen AD, Xanthoulea S, Blok MJ, Romano A. Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 2017;18(2):308. - PMC - PubMed
    1. Pasmans CT, Tops BB, Steeghs EM, Coupé VM, Grünberg K, de Jong EK, Schuuring EM, Willems SM, Ligtenberg MJ, Retèl VP, van Snellenberg H. Micro-costing diagnostics in oncology: from single-gene testing to whole-genome sequencing. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):413–4. - PubMed
    1. Kulkarni N, Tank S, Korlekar P, Shidhaye S, Barve P. A review of gene mutations, conventional testing and novel approaches to cancer screening. Int J Exp Res Rev. 2023;30:134–62.

LinkOut - more resources